benzoic acid/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to the treatment of cancer using derivatives of p-amino-benzoic acid (PABA). The invention also relates to the potentiation of radiotherapy, chemotherapy, or a combination thereof, with PABA derivatives that are agonists of the PXR/SXR xenobiotic

FIELD OF THE INVENTION The present invention relates to the treatment of cancer using derivatives of p-amino-benzoic acid (PABA). The invention also relates to the potentiation of radiotherapy, chemotherapy, or a combination thereof, with PABA derivatives that are agonists of the PXR/SXR xenobiotic

FIELD OF THE INVENTION The present invention relates to the treatment of cancer using the sodium salt of a derivative of p-amino-benzoic acid (PABA). The invention also relates to the potentiation of radiotherapy, chemotherapy, or a combination thereof, with the sodium salt of the PABA

BACKGROUND OF THE INVENTION 1. Field of the Invention Some chondrogenetic disorders and dermatological disorders such as psoriasis and malignant disorders such as leukemia can be looked upon as a disease involving a block or an abnormality in differentiation. The present invention relates to novel

FIELD OF THE INVENTION The present invention relates a MDM2 inhibitor that is useful as therapeutic agent, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain the MDM2 inhibitor. BACKGROUND OF THE INVENTION p53 is a tumor suppressor and

The present invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting

The present invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting

FIELD OF THE INVENTION This invention provides benzoic acid and amide derivatives of anthranilic acids which inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer and restenosis. BACKGROUND OF THE INVENTION Proliferative diseases are caused by a defect in

FIELD OF THE INVENTION This invention provides benzoic acid and amide derivatives of anthranilic acids which inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer and restenosis. BACKGROUND OF THE INVENTION Proliferative diseases are caused by a defect in

RELATED PATENTS AND RELATED COPENDING APPLICATIONS The present invention is related to U.S. Pat. Nos. 6,117,845; 5,663,377; 5,599,953; 5,574,177; and 5,516,792, which are incorporated herein by reference. The present invention is also related to co-pending U.S. patent application Ser. No.

FIELD OF THE INVENTION This invention provides benzoic acid and amide derivatives of anthranilic acids which inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer and restenosis. BACKGROUND OF THE INVENTION Proliferative diseases are caused by a defect in

BACKGROUND OF THE INVENTION (a) Field of the Invention The invention relates to a photodynamic treatment for the selective destruction of malignant leukemic cells without affecting the normal cells and without causing systemic toxicity for the patient. (b) Description of Prior Art Cancers are

BACKGROUND OF THE INVENTION (a) Field of the Invention The invention relates to a photodynamic treatment for the selective destruction of malignant leukemic cells without affecting the normal cells and without causing systemic toxicity for the patient. (b) Description of Prior Art Cancers are

FIELD OF THE INVENTION BACKGROUND OF THE INVENTION Medicaments according to the prior art which are employed in chemotherapy as a rule only achieve partial success, i.e. they do not lead to a final cure. Moreover, the substances employed in the prior art frequently act only in a certain tumor

BACKGROUND OF THE INVENTION Field of the Invention Medicaments according to the prior art which are employed in chemotherapy as a rule only achieve partial success, i.e. they do not lead to a final cure. Moreover, the substances employed in the prior art frequently act only in a certain tumor